Oncology Institute Repays $86M Convertible Note, Secures New Debt with OrbiMed, Avoiding Dilution
TOI has more than doubled off its 52-week low of $2.32.
Summary
The Oncology Institute completed a strategic refinancing, repaying its $86 million convertible note from Deerfield Partners. The company secured new credit facilities from OrbiMed, including a $75 million term loan maturing in 2031, and used $11 million in cash. This move significantly strengthens the balance sheet, improves liquidity, and extends debt maturities. Crucially, the refinancing was achieved without diluting existing shareholders, removing potential future dilution risk from the convertible note. This follows the company's strong Q1 2026 financial results reported in May.
At the time of this announcement, TOI was trading at $5.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $543.9M. The 52-week trading range was $2.32 to $5.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.